Resources

Past Presentation

HCV Direct Acting Antiviral Treatment Interruptions | February 5, 2025

Date of Presentation: February 5, 2025

Type: Past Presentation  

Audience: Clinical  

Program: Hepatitis C  

Keywords: #daa  #direct acting antiviral  #hcv  #missed doses  #treatment interruption  

In this presentation, Dr. Paulina Deming, PharmD, PhC, RPh, discusses how to apply the guidance provided by the Infectious Diseases Society of America (IDSA) and the American Association for the Study of Liver Diseases (AASLD) on HCV DAA treatment interruptions, identify when patients should have DAA therapy continued vs when DAA therapy should be stopped, and also describes the data in patients with incomplete adherence.

Recording:

Presented by:

Dr. Paulina Deming
Dr. Paulina Deming

Dr. Paulina Deming is an Associate Professor-Clinical Educator within the Pharmacy Practice and Administrative Sciences Department at the College of Pharmacy at the University of New Mexico Health Sciences Center (UNMHSC). Dr. Deming completed a general practice residency and infectious diseases pharmacotherapy residency at UNMHSC. Her interests are focused in hepatitis C virus (HCV) infections and clinical therapeutics. She is the assistant director for the Project ECHO (Extension for Community Healthcare Outcomes) HCV clinic and serves on Project ECHO’s expert faculty panel advising providers on HCV care in community, corrections, and within the Indian Health Services settings. Licensed as a pharmacist clinician, she sees patients through the UNMHSC’s HCV clinic and the Truman HCV-HIV coinfection clinic. In addition to teaching and clinical work, Dr. Deming has co-authored papers on the management of HCV infections as well as HCV treatment outcomes in real-world settings.

Read the full bio …

Resources Provided:

Date added: January 24, 2025